NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Open in Screener

ITOS

ITeos Therapeutics Inc

May 16 • 04:00PM ET

7.81

Dollar change -0.16
Percentage change -2.01	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA AZN BMY GILD AMGN PFE JNJ REGN VRTX INCY

| Held by: VTI IWM VXF IWN DFAT IBB SCHA VTWO DFAS PRFZ

Index	RUT	P/E	-	EPS (ttm)	-3.23	Insider Own	13.52%	Shs Outstand	38.27M	Perf Week	17.18%
Market Cap	298.92M	Forward P/E	-	EPS next Y	-2.46	Insider Trans	106.74%	Shs Float	33.08M	Perf Month	25.56%
Income	-130.81M	PEG	-	EPS next Q	-0.78	Inst Own	107.19%	Short Float	7.65%	Perf Quarter	5.54%
Sales	35.00M	P/S	8.54	EPS this Y	12.53%	Inst Trans	-0.91%	Short Ratio	3.39	Perf Half Y	-15.02%
Book/sh	14.72	P/B	0.53	EPS next Y	15.44%	ROA	-20.30%	Short Interest	2.53M	Perf Year	-53.29%
Cash/sh	13.60	P/C	0.57	EPS next 5Y	3.89%	ROE	-23.68%	52W Range	4.80 - 18.70	Perf YTD	1.69%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-34.39%	ROI	-23.07%	52W High	-58.24%	Beta	1.40
Dividend TTM	-	Quick Ratio	14.13	Sales past 5Y	12.04%	Gross Margin	96.41%	52W Low	62.71%	ATR (14)	0.56
Dividend Ex-Date	-	Current Ratio	14.13	EPS Y/Y TTM	14.60%	Oper. Margin	-435.19%	RSI (14)	59.73	Volatility	7.86% 7.61%
Employees	173	Debt/Eq	0.01	Sales Y/Y TTM	177.89%	Profit Margin	-373.75%	Recom	2.00	Target Price	12.17
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	24.92%	Payout	-	Rel Volume	1.56	Prev Close	7.97
Sales Surprise	-100.00%	EPS Surprise	15.79%	Sales Q/Q	-	Earnings	Apr 28 AMC	Avg Volume	746.58K	Price	7.81
SMA20	8.30%	SMA50	16.71%	SMA200	-15.45%	Trades		Volume	1,163,443	Change	-2.01%

Date	Action	Analyst	Rating Change	Price Target Change
May-14-25	Downgrade	Leerink Partners	Outperform → Market Perform	$9
May-14-25	Downgrade	H.C. Wainwright	Buy → Neutral
May-13-25	Downgrade	JP Morgan	Overweight → Neutral
Aug-13-24	Initiated	Wells Fargo	Overweight	$31
May-05-21	Initiated	H.C. Wainwright	Buy	$37
Oct-08-20	Initiated	Robert W. Baird	Outperform	$45
Aug-18-20	Initiated	Wedbush	Outperform	$45
Aug-18-20	Initiated	SVB Leerink	Outperform	$45
Aug-18-20	Initiated	Piper Sandler	Overweight	$50
Aug-18-20	Initiated	JP Morgan	Overweight	$40

May-15-25 07:55AM	GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug (Zacks)
May-14-25 06:00AM	GSK and iTeos drop anti-TIGIT drug following trial failure (Clinical Trials Arena)
May-13-25 12:35PM	iTeos Stock Soars Despite Trial Setback On Liquidation Buzz And Solid Cash Pile (Benzinga) +13.44%
07:55AM	iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients (GlobeNewswire)
07:10AM	iTeos, GSK to shelve TIGIT drug after study setback (BioPharma Dive)
09:55AM	Loading…
May-02-25 09:55AM	Wall Street Analysts See a 211.07% Upside in iTeos Therapeutics (ITOS): Can the Stock Really Move This High? (Zacks)
Apr-28-25 04:30PM	iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-25-25 04:35PM	iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025 (GlobeNewswire) -5.44%
Mar-13-25 09:55AM	Wall Street Analysts Think iTeos Therapeutics (ITOS) Could Surge 212.5%: Read This Before Placing a Bet (Zacks)
Mar-05-25 07:00AM	iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire) +5.99%
Jan-13-25 12:00PM	All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy (Zacks)
Jan-10-25 07:00AM	iTeos Announces 2025 Strategic Priorities and Anticipated Milestones (GlobeNewswire)
Jan-08-25 07:00AM	iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-20-24 07:20AM	iTeos Therapeutics price target lowered to $19 from $31 at Wells Fargo (TipRanks)
Dec-13-24 01:25PM	Inupadenant deprioritised by iTeos in favour of pipeline TIGIT therapy (Clinical Trials Arena)
08:55AM	Loading…
Dec-12-24 08:55AM	iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress (GlobeNewswire)
Nov-26-24 07:00AM	iTeos to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-12-24 07:00AM	iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Oct-24-24 07:00AM	iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress (GlobeNewswire)
Oct-16-24 01:01AM	BOXER CAPITAL, LLC Expands Stake in ITeos Therapeutics Inc (GuruFocus.com)
Sep-30-24 01:01PM	TANG CAPITAL MANAGEMENT LLC Acquires New Stake in ITeos Therapeutics Inc (GuruFocus.com)
Sep-16-24 04:04PM	Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths (Investor's Business Daily) -27.54%
Sep-15-24 09:12PM	ESMO 2024: TIGIT race tightens with first look at GSK/iTeoss TIGIT in NSCLC (Pharmaceutical Technology)
Sep-14-24 08:10AM	TIGIT drug from iTeos shrinks lung tumors in trial (BioPharma Dive)
02:30AM	iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients (GlobeNewswire)
Aug-28-24 04:30PM	iTeos to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-20-24 08:30AM	iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024 (GlobeNewswire) +10.13%
Aug-08-24 08:20AM	ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	iTeos Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-05-24 07:00AM	iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer (GlobeNewswire)
12:33PM	Loading…
Jul-09-24 12:33PM	iTeos and GSK hit enrolment milestone with Phase III TIGIT lung cancer trial (Pharmaceutical Technology)
Jul-08-24 07:00AM	iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK (GlobeNewswire)
Jun-18-24 06:33AM	iTeos Therapeutics and GSK begin Phase III trial of combination therapy for NSCLC (Clinical Trials Arena)
Jun-17-24 09:00AM	iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer (GlobeNewswire) -6.04%
May-13-24 08:28AM	HC Wainwright Adjusts Price Target on iTeos Therapeutics to $46 From $44, Maintains Buy Rating (MT Newswires)
May-10-24 01:53PM	ITOS Stock Earnings: ITeos Therapeutics Beats EPS for Q1 2024 (InvestorPlace) +43.07%
12:21PM	Wedbush Adjusts iTeos Therapeutics' Price Target to $21 From $18, Maintains Outperform Rating (MT Newswires)
09:40AM	iTeos Therapeutics Q1 Net Loss Widens; Initiates $120 Million Registered Direct Offering -- Shares Jump (MT Newswires)
08:26AM	iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
08:24AM	iTeos Therapeutics Announces $120 Million Registered Direct Offering (GlobeNewswire)
08:09AM	iTeos shares jump on TIGIT update; Acelyrin swaps CEOs (BioPharma Dive)
Apr-07-24 04:30PM	iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-06-24 02:51PM	ITOS Stock Earnings: ITeos Therapeutics Beats EPS for Q4 2023 (InvestorPlace) +7.80%
07:01AM	iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors (GlobeNewswire)
07:00AM	iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-05-24 04:30PM	iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-01-24 07:00AM	iTeos to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.23%
Feb-26-24 06:11AM	Strength Seen in iTeos Therapeutics, Inc. (ITOS): Can Its 7.4% Jump Turn into More Strength? (Zacks)
Jan-08-24 07:00AM	iTeos Announces 2024 Strategic Priorities and Anticipated Milestones (GlobeNewswire)
Jan-03-24 07:00AM	iTeos to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-13-23 09:55AM	Wall Street Analysts Believe iTeos Therapeutics, Inc. (ITOS) Could Rally 243.43%: Here's is How to Trade (Zacks)
Nov-27-23 09:55AM	Does iTeos Therapeutics, Inc. (ITOS) Have the Potential to Rally 283.59% as Wall Street Analysts Expect? (Zacks) -5.44%
Nov-21-23 07:00AM	iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-13-23 09:55AM	Here's Why iTeos Therapeutics, Inc. (ITOS) Could be Great Choice for a Bottom Fisher (Zacks)
Nov-10-23 09:55AM	Wall Street Analysts Predict a 304.26% Upside in iTeos Therapeutics, Inc. (ITOS): Here's What You Should Know (Zacks)
Nov-07-23 07:00AM	iTeos Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Oct-31-23 03:01AM	Viridian Therapeutics, Inc. (VRDN) Stock Jumps 5.2%: Will It Continue to Soar? (Zacks) +7.48%
Oct-16-23 01:46PM	Hedge Fund and Insider Trading News: Ken Griffin, EcoR1 Capital, Glen Point Capital, JAT Capital, Eisler Capital, Elliott Management, iTeos Therapeutics Inc (ITOS), Funko, Inc. (FNKO), and More (Insider Monkey)
04:38AM	iTeos Therapeutics, Inc. (ITOS) Stock Jumps 5.4%: Will It Continue to Soar? (Zacks)
Oct-11-23 05:55PM	NCR Atleos Set to Join S&P SmallCap 600 (PR Newswire) -6.72% -6.39%
Sep-06-23 07:00AM	iTeos to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-26-23 11:02AM	BOXER CAPITAL, LLC Reduces Stake in ITeos Therapeutics Inc (GuruFocus.com)
Aug-24-23 11:30AM	Biotech Stocks Rally After Roche's (RHHBY) Accidental Data Leak (Zacks)
Aug-23-23 04:10PM	Why Roche's Accidental Cancer Update Boosted Several Rivals By As Much As 22% (Investor's Business Daily) +14.89%
02:00PM	Watertown biotech shares spike after accidental data publication at Roche (American City Business Journals)
09:24AM	How Roche's Accidental Cancer Update Lifted Iteos And Arcus More Than 30% (Investor's Business Daily)
Aug-08-23 07:00AM	iTeos Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Jun-21-23 08:00PM	ITOS: Lowering target price to $11.00 (Argus Research)
May-13-23 08:03AM	Broker Revenue Forecasts For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Are Surging Higher (Simply Wall St.)
May-11-23 06:11AM	iTeos Therapeutics First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-10-23 08:35AM	ITeos Therapeutics, Inc. (ITOS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:01AM	iTeos Reports First Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
May-05-23 08:51AM	iTeos Therapeutics (NASDAQ:ITOS) shareholders have endured a 46% loss from investing in the stock a year ago (Simply Wall St.)
Apr-26-23 08:00PM	ITOS: What does Argus have to say about ITOS? (Argus Research)
Mar-23-23 01:56PM	Down More Than 50%: 2 Strong Buy Stocks That Are Too Cheap to Ignore (TipRanks)
Mar-21-23 06:07AM	Take Care Before Jumping Onto iTeos Therapeutics, Inc. (NASDAQ:ITOS) Even Though It's 25% Cheaper (Simply Wall St.)
Mar-17-23 06:18AM	Time To Worry? Analysts Are Downgrading Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Outlook (Simply Wall St.)
Mar-15-23 08:35AM	ITeos Therapeutics, Inc. (ITOS) Q4 Earnings and Revenues Surpass Estimates (Zacks)
07:00AM	iTeos Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-28-23 07:00AM	iTeos to Present at Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-07-23 01:51PM	The 7 Best Biotech Stocks to Buy for February 2023 (InvestorPlace)
07:00AM	iTeos to Present at SVB Securities Global Biopharma Conference (GlobeNewswire)
Feb-02-23 02:19PM	The 7 Most Undervalued Biotech Stocks to Buy in February 2023 (InvestorPlace)
Jan-09-23 07:00AM	iTeos Provides Business Updates and Clinical Development Plans for 2023 (GlobeNewswire)
Jan-03-23 07:00AM	iTeos to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.07%
Dec-07-22 08:07AM	Could The Market Be Wrong About iTeos Therapeutics, Inc. (NASDAQ:ITOS) Given Its Attractive Financial Prospects? (Simply Wall St.)
Nov-22-22 07:00AM	iTeos to Present at the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire) -5.98%
Nov-10-22 07:55PM	ITeos Therapeutics, Inc. (ITOS) Lags Q3 Earnings and Revenue Estimates (Zacks) +11.14%
04:01PM	iTeos Reports Third Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-04-22 05:46PM	Top Biotech Stocks for Q4 2022 (Investopedia)
Nov-02-22 10:00AM	ITeos Therapeutics, Inc. (ITOS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-18-22 08:36AM	Shareholders in iTeos Therapeutics (NASDAQ:ITOS) are in the red if they invested a year ago (Simply Wall St.)
Aug-12-22 06:16AM	iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Cut Their EPS Forecasts Substantially (Simply Wall St.) +7.00%
Aug-10-22 05:25PM	ITeos Therapeutics, Inc. (ITOS) Q2 Earnings and Revenues Lag Estimates (Zacks) -12.51%
04:01PM	iTeos Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Aug-02-22 07:00AM	iTeos to Present at the 2022 Wedbush PacGrow Healthcare Conference (GlobeNewswire)
Jun-30-22 08:41AM	iTeos Therapeutics, Inc. (NASDAQ:ITOS) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? (Simply Wall St.)
May-16-22 06:27AM	Forecast: Analysts Think iTeos Therapeutics, Inc.'s (NASDAQ:ITOS) Business Prospects Have Improved Drastically (Simply Wall St.)
May-12-22 05:45PM	ITeos Therapeutics, Inc. (ITOS) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
04:01PM	iTeos Reports First Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
EcoR1 Capital, LLC	10% Owner	May 15 '25	Buy	8.00	3,300,000	26,400,000	10,688,978	May 16 06:52 PM
EcoR1 Capital, LLC	10% Owner	May 14 '25	Buy	7.41	1,658,978	12,285,562	7,388,978	May 16 06:52 PM
GADICKE ANSBERT	Former 10% Owner	May 13 '25	Sale	8.06	1,031,931	8,317,364	3,452,797	May 15 05:34 PM
MPM BIOVENTURES 2018, L.P.	Former 10% Owner	May 13 '25	Sale	8.06	630,191	5,079,339	2,108,594	May 15 05:33 PM
MPM BioVentures 2014, L.P.	Former 10% Owner	May 13 '25	Sale	8.06	630,191	5,079,339	2,108,594	May 15 05:32 PM
Van Hauwermeiren Timothy	Director	May 13 '25	Option Exercise	4.30	22,346	96,088	22,346	May 14 08:00 PM
Gall Matthew	Chief Financial Officer	Nov 19 '24	Buy	7.73	5,000	38,635	65,429	Nov 19 07:59 PM

Dollar change 0.00
Percentage change 0.00	%

HOWL Werewolf Therapeutics Inc daily Stock Chart

Peers: CRSP NTLA BLUE BMRN EDIT RCKT SGMO CLLS ADVM SLDB

| Held by: VTI IWM VXF IWN VTWO IWO IWC RSSL VTWV VTWG

Index	RUT	P/E	-	EPS (ttm)	-1.64	Insider Own	26.37%	Shs Outstand	44.83M	Perf Week	38.78%
Market Cap	49.81M	Forward P/E	-	EPS next Y	-1.62	Insider Trans	4.67%	Shs Float	33.12M	Perf Month	30.90%
Income	-72.41M	PEG	-	EPS next Q	-0.48	Inst Own	47.51%	Short Float	6.49%	Perf Quarter	-25.50%
Sales	1.14M	P/S	43.69	EPS this Y	-9.00%	Inst Trans	-32.21%	Short Ratio	7.55	Perf Half Y	-48.37%
Book/sh	1.28	P/B	0.87	EPS next Y	8.72%	ROA	-50.84%	Short Interest	2.15M	Perf Year	-77.48%
Cash/sh	2.05	P/C	0.54	EPS next 5Y	-3.48%	ROE	-82.81%	52W Range	0.60 - 5.73	Perf YTD	-25.00%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-20.76%	ROI	-77.94%	52W High	-80.63%	Beta	0.61
Dividend TTM	-	Quick Ratio	8.09	Sales past 5Y	-13.79%	Gross Margin	-55.38%	52W Low	86.55%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	8.09	EPS Y/Y TTM	-50.02%	Oper. Margin	-6511.20%	RSI (14)	62.43	Volatility	14.29% 10.63%
Employees	46	Debt/Eq	0.65	Sales Y/Y TTM	-92.95%	Profit Margin	-6335.17%	Recom	1.00	Target Price	9.67
Option/Short	Yes / Yes	LT Debt/Eq	0.62	EPS Q/Q	-3.67%	Payout	-	Rel Volume	2.71	Prev Close	1.11
Sales Surprise	-	EPS Surprise	-1.32%	Sales Q/Q	-100.00%	Earnings	May 08 BMO	Avg Volume	284.66K	Price	1.11
SMA20	20.60%	SMA50	16.21%	SMA200	-32.53%	Trades		Volume	770,922	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-03-24	Initiated	JMP Securities	Mkt Outperform	$12
Aug-24-23	Initiated	Wedbush	Outperform	$9
Jun-06-23	Resumed	Jefferies	Buy	$11 → $12
Sep-10-21	Initiated	BofA Securities	Buy	$26
May-25-21	Initiated	SVB Leerink	Outperform	$29
May-25-21	Initiated	Jefferies	Buy	$22
May-25-21	Initiated	H.C. Wainwright	Buy	$32
May-25-21	Initiated	Evercore ISI	Outperform	$23

May-13-25 08:00AM	Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit (GlobeNewswire)
May-08-25 07:00AM	Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -5.54%
May-06-25 05:10PM	Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-05-25 08:05AM	Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting (GlobeNewswire)
08:00AM	Werewolf Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
10:00AM	Loading…
Apr-25-25 10:00AM	Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline (Zacks)
Apr-17-25 08:00AM	Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer (GlobeNewswire) +8.37%
Mar-31-25 08:00AM	Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire) -5.61%
Mar-11-25 07:00AM	Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-04-25 08:00AM	Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-24-25 07:30AM	Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors (GlobeNewswire)
Jan-14-25 08:35AM	Werewolf Therapeutics provides business update, highlights 2025 outlook (TipRanks)
Jan-13-25 08:00AM	Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook (GlobeNewswire)
Nov-20-24 08:00AM	Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference (GlobeNewswire)
Nov-07-24 09:02AM	Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting (GlobeNewswire) -8.20%
09:00AM	Loading…
09:00AM	Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-31-24 08:00AM	Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE Molecule for Inflammatory Diseases (GlobeNewswire) -5.02%
Oct-20-24 06:04AM	Bank of America Predicts up to ~390% Surge for These 2 Strong Buy Stocks (TipRanks)
Oct-04-24 09:00AM	Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting (GlobeNewswire)
Sep-03-24 08:00AM	Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -5.09%
Aug-08-24 08:15AM	Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +8.19%
07:05AM	Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jun-25-24 07:00AM	Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma (GlobeNewswire) -10.34%
Jun-01-24 09:00AM	Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors (GlobeNewswire)
May-30-24 08:00AM	Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference (GlobeNewswire) +5.30%
May-23-24 05:00PM	Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting (GlobeNewswire) +5.52% -5.43%
May-03-24 01:53PM	HOWL Stock Earnings: Werewolf Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
07:00AM	Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-24-24 10:05AM	Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-23-24 08:00AM	Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting (GlobeNewswire) +5.75%
12:00PM	Loading…
Apr-15-24 12:00PM	All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy (Zacks) +17.06%
Apr-05-24 04:30PM	Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting (GlobeNewswire) -9.12%
Apr-04-24 04:30PM	Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR Platform in Immunology-Based Diseases at AAI Annual Meeting (GlobeNewswire)
Mar-12-24 09:55AM	How Much Upside is Left in Werewolf Therapeutics, Inc. (HOWL)? Wall Street Analysts Think 92.37% (Zacks)
Mar-07-24 02:52PM	HOWL Stock Earnings: Werewolf Therapeutics Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
08:45AM	Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-06-24 08:00AM	Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference (GlobeNewswire)
Mar-05-24 04:30PM	Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024 (GlobeNewswire)
Jan-08-24 07:00AM	Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook (GlobeNewswire)
Jan-04-24 04:05PM	Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors (GlobeNewswire) +20.69%
Nov-22-23 07:00AM	Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-14-23 04:25PM	Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-03-23 07:00AM	Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting (GlobeNewswire) +47.44%
Oct-31-23 09:00AM	Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting (GlobeNewswire)
Oct-27-23 04:58AM	Strength Seen in Exelixis (EXEL): Can Its 5.6% Jump Turn into More Strength? (Zacks) +6.49%
Sep-27-23 09:00AM	Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer s (SITC) 38th Annual Meeting (GlobeNewswire) +11.00%
Sep-11-23 04:05PM	Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124 (GlobeNewswire)
Sep-05-23 04:05PM	Werewolf Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-24-23 09:57AM	Nvidia upgraded, Estee Lauder downgraded: Wall Street's top analyst calls (The Fly) +26.74%
Aug-13-23 08:04AM	Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? (Simply Wall St.)
Aug-11-23 03:21PM	Werewolf Therapeutics Second Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
Aug-10-23 08:25AM	Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:10AM	Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jun-30-23 06:10AM	Institutions profited after Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) market cap rose US$11m last week but private equity firms profited the most (Simply Wall St.) +5.90%
Jun-01-23 07:00AM	Werewolf Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire) +14.42%
May-11-23 08:35AM	Werewolf Therapeutics, Inc. (HOWL) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -8.88%
07:00AM	Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-01-23 07:00AM	Werewolf Therapeutics to Participate in May Investor Conferences (GlobeNewswire) +5.49%
Apr-19-23 10:00AM	Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE Molecule, in Cancer Immunology Research (GlobeNewswire)
Mar-23-23 08:25AM	Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -5.24%
07:00AM	Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-16-23 07:30AM	UPDATE -- Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023 (GlobeNewswire)
Mar-15-23 07:30AM	Werewolf Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2023 (GlobeNewswire)
Feb-24-23 07:30AM	Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330 (GlobeNewswire) -13.77%
Feb-17-23 05:08AM	Investors in Werewolf Therapeutics (NASDAQ:HOWL) have unfortunately lost 53% over the last year (Simply Wall St.)
Feb-07-23 07:00AM	Werewolf Therapeutics to Present at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-20-23 05:16AM	Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) top owners are private equity firms with 42% stake, while31% is held by institutions (Simply Wall St.) +22.51%
Dec-12-22 10:22AM	Is Werewolf Therapeutics (NASDAQ:HOWL) In A Good Position To Deliver On Growth Plans? (Simply Wall St.) +7.26%
Nov-10-22 09:00AM	Werewolf Therapeutics Presents Preclinical Data on mWTX-330, a Surrogate IL-12 INDUKINE Molecule, at the Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
08:15AM	Werewolf Therapeutics, Inc. (HOWL) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Werewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-07-22 04:05PM	Werewolf Therapeutics to Present Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting and Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-07-22 07:00AM	Werewolf Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Sep-01-22 07:00AM	Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1/1b Clinical Trial of WTX-124 for the Treatment of Patients with Selected Solid Tumors (GlobeNewswire) +19.57%
Aug-15-22 06:45AM	Shareholders in Werewolf Therapeutics (NASDAQ:HOWL) are in the red if they invested a year ago (Simply Wall St.)
Aug-11-22 07:00AM	Werewolf Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights (GlobeNewswire) +14.02%
Aug-03-22 07:00AM	Werewolf Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference (GlobeNewswire)
Jul-05-22 07:54AM	We Think Werewolf Therapeutics (NASDAQ:HOWL) Needs To Drive Business Growth Carefully (Simply Wall St.)
Jun-06-22 04:51PM	Werewolf Therapeutics to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference (GlobeNewswire) +21.22%
May-10-22 07:00AM	Werewolf Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights (GlobeNewswire) +10.95%
Apr-08-22 02:29PM	JAZZ Inks Deal With Werewolf to Add Oncology Candidate (Zacks)
01:00PM	Werewolf Therapeutics Presents Promising Preclinical Data on its Two Lead INDUKINE Molecules at AACR 2022 Annual Meeting (GlobeNewswire)
Apr-07-22 09:25AM	Werewolf Therapeutics Shares Jump On Cancer Product Pact With Jazz Pharma (Benzinga) +23.47%
08:34AM	Jazz, Werewolf sign licensing deal worth up to $1.2 billion (MarketWatch)
07:00AM	Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFN INDUKINE Molecule (PR Newswire)
Mar-24-22 07:00AM	Werewolf Therapeutics Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Business Highlights (GlobeNewswire)
Mar-16-22 08:00AM	Werewolf Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy of WTX-124 in Delivering IL-2 Selectively to the Tumor Microenvironment (GlobeNewswire)
Mar-15-22 08:00AM	Werewolf Therapeutics Announces Upcoming Presentations at AACR 2022 Annual Meeting (GlobeNewswire)
Feb-08-22 08:00AM	Werewolf Therapeutics to Present at the SVB Leerink Global Healthcare Conference (GlobeNewswire)
Jan-26-22 06:53AM	Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Jan-05-22 08:00AM	Werewolf Therapeutics to Present at the H.C. Wainwright Bioconnect Conference (GlobeNewswire)
Dec-14-21 04:01PM	Werewolf Therapeutics Added to the Nasdaq Biotechnology Index (GlobeNewswire)
Dec-01-21 08:00AM	Werewolf Therapeutics to Present Preclinical Data on INDUKINE Molecules at the 63rd American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) -5.45%
Nov-10-21 07:00AM	Werewolf Therapeutics Reports Third Quarter 2021 Financial Results and Business Update (GlobeNewswire)
Nov-08-21 08:03AM	Werewolf Therapeutics to Present at Upcoming Conferences in November 2021 (GlobeNewswire)
Oct-28-21 04:01PM	Werewolf Therapeutics Appoints Meeta Chatterjee, Ph.D., to its Board of Directors (GlobeNewswire)
Oct-27-21 07:30AM	Werewolf Therapeutics to Present Data on its INDUKINE Product Candidates at the Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Sep-14-21 08:00AM	Werewolf Therapeutics to Present at Upcoming Next-Gen Cytokine Therapeutics Summit (GlobeNewswire)
Sep-08-21 08:00AM	Werewolf Therapeutics to Present at H. C. Wainwright Global Investment Conference (GlobeNewswire) -6.16%

Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The firm offers Predator Technology which focuses on immune targeting and activation. The company was founded by Daniel J. Hicklin, Patrick A. Baeuerle, and Luke B. Evnin on October 19, 2017 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RA CAPITAL MANAGEMENT, L.P.	Director	May 12 '25	Buy	0.86	320,913	275,985	6,021,969	May 14 06:08 PM
RA CAPITAL MANAGEMENT, L.P.	Director	May 14 '25	Buy	0.98	162,539	159,288	6,237,482	May 14 06:08 PM
RA CAPITAL MANAGEMENT, L.P.	Director	May 13 '25	Buy	0.98	52,974	51,915	6,074,943	May 14 06:08 PM
MPM BioVentures 2014, L.P.	10% Owner	Mar 27 '25	Sale	1.05	1,963	2,061	3,208,793	Apr 30 04:17 PM
EVNIN LUKE	Director	Mar 27 '25	Sale	1.05	2,425	2,546	4,309,860	Apr 30 04:09 PM
GADICKE ANSBERT	10% Owner	Mar 27 '25	Sale	1.05	4,386	4,605	6,718,670	Apr 30 04:08 PM

Dollar change -0.03
Percentage change -0.37	%

TRDA Entrada Therapeutics Inc daily Stock Chart

Peers: MRNA REGN PFE GILD BNTX NVAX VRTX SRPT INCY RNA

| Held by: VTI IWM VXF IWN VTWO IBB SCHA FDM VHT DFSV

Index	RUT	P/E	10.01	EPS (ttm)	0.81	Insider Own	41.48%	Shs Outstand	37.94M	Perf Week	-3.46%
Market Cap	307.04M	Forward P/E	-	EPS next Y	-4.19	Insider Trans	-0.71%	Shs Float	22.21M	Perf Month	2.93%
Income	24.78M	PEG	-	EPS next Q	-0.83	Inst Own	52.95%	Short Float	4.79%	Perf Quarter	-39.81%
Sales	172.22M	P/S	1.78	EPS this Y	-292.56%	Inst Trans	-0.58%	Short Ratio	7.64	Perf Half Y	-59.12%
Book/sh	11.00	P/B	0.74	EPS next Y	-29.53%	ROA	4.97%	Short Interest	1.06M	Perf Year	-42.99%
Cash/sh	10.08	P/C	0.80	EPS next 5Y	-	ROE	7.22%	52W Range	7.10 - 21.79	Perf YTD	-53.21%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	5.30%	52W High	-62.87%	Beta	-0.03
Dividend TTM	-	Quick Ratio	21.88	Sales past 5Y	12.68%	Gross Margin	97.83%	52W Low	13.94%	ATR (14)	0.59
Dividend Ex-Date	-	Current Ratio	21.88	EPS Y/Y TTM	24.45%	Oper. Margin	2.39%	RSI (14)	41.46	Volatility	6.40% 6.85%
Employees	183	Debt/Eq	0.14	Sales Y/Y TTM	5.74%	Profit Margin	14.39%	Recom	1.00	Target Price	23.67
Option/Short	Yes / Yes	LT Debt/Eq	0.12	EPS Q/Q	-162.54%	Payout	0.00%	Rel Volume	1.56	Prev Close	8.12
Sales Surprise	102.12%	EPS Surprise	46.74%	Sales Q/Q	-65.23%	Earnings	May 08 BMO	Avg Volume	139.28K	Price	8.09
SMA20	-6.30%	SMA50	-11.07%	SMA200	-43.24%	Trades		Volume	217,153	Change	-0.37%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-06-24	Initiated	ROTH MKM	Buy	$29
Jan-05-24	Initiated	Oppenheimer	Outperform	$22
Apr-03-23	Initiated	H.C. Wainwright	Buy	$25

May-08-25 08:15AM	Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +5.64%
07:00AM	Entrada Therapeutics Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-01-25 10:01AM	Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release (Zacks)
08:00AM	Arvinas, Entrada cut staff; Merck builds US hub for Keytruda (BioPharma Dive)
Apr-29-25 10:01AM	Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for (Zacks)
09:30AM	Loading…
Apr-10-25 09:30AM	Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock? (Zacks) -5.08%
Mar-26-25 10:17AM	The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs (SeekingAlpha)
Mar-25-25 10:03AM	Entrada gains UK MHRA authorisation to start Phase I/II trial of DMD treatment (Clinical Trials Arena) -5.79%
Mar-24-25 07:00AM	Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping (GlobeNewswire)
Feb-27-25 08:25AM	Entrada Therapeutics, Inc. (TRDA) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
07:00AM	Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-26-25 06:11AM	AstraZenecas next breast cancer drug; Madrigals accelerating MASH launch (BioPharma Dive)
Feb-25-25 01:05PM	FDA removes clinical hold on Entradas Duchenne therapy (Clinical Trials Arena) -5.68%
Feb-24-25 07:00AM	Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44 (GlobeNewswire)
Feb-12-25 07:58AM	Entrada Therapeutics, Inc. (TRDA): A Cheap Biotech Stock to Invest In Now (Insider Monkey)
07:19AM	Loading…
Feb-04-25 07:19AM	Entrada gets UK MHRA authorisation to begin Phase I/II trial of DMD treatment (Clinical Trials Arena)
Feb-03-25 07:00AM	Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy (GlobeNewswire)
Jan-30-25 04:05PM	Azenta Announces the Election of Dipal Doshi to its Board of Directors (PR Newswire)
Dec-18-24 07:00AM	Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -7.32%
Dec-07-24 05:25AM	Roth MKM starts overlooked Entrada Therapeutics with Buy rating (TipRanks)
Nov-25-24 08:50AM	Entrada Therapeutics (TRDA) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Nov-05-24 08:15AM	Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Entrada Therapeutics Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-09-24 07:00AM	Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society (GlobeNewswire)
Sep-24-24 07:00AM	Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development (GlobeNewswire) +5.70%
Sep-17-24 08:30AM	ashibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors (Business Wire)
Sep-06-24 07:00AM	Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program (GlobeNewswire)
Aug-13-24 08:20AM	Entrada Therapeutics, Inc. (TRDA) Tops Q2 Earnings and Revenue Estimates (Zacks) +11.26%
07:00AM	Entrada Therapeutics Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-25-24 09:55AM	Wall Street Analysts See a 25.73% Upside in Entrada Therapeutics (TRDA): Can the Stock Really Move This High? (Zacks) +5.75%
09:33AM	Loading…
Jul-12-24 09:33AM	Entrada Therapeutics (TRDA) Moves 10.4% Higher: Will This Strength Last? (Zacks)
Jun-24-24 07:15AM	Entrada Therapeutics Announces $100 Million Registered Direct Offering (GlobeNewswire)
06:00AM	Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy (GlobeNewswire)
Jun-03-24 07:00AM	Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-21-24 09:55AM	Wall Street Analysts Think Entrada Therapeutics (TRDA) Could Surge 37.08%: Read This Before Placing a Bet (Zacks)
May-20-24 05:32PM	Entrada Therapeutics Insider Sold Shares Worth $287,695, According to a Recent SEC Filing (MT Newswires)
May-16-24 07:02PM	Director Peter Kim Acquires 25,000 Shares of Entrada Therapeutics Inc (TRDA) (GuruFocus.com)
04:35PM	Entrada Therapeutics Insider Bought Shares Worth $364,673, According to a Recent SEC Filing (MT Newswires)
07:00AM	Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-07-24 01:53PM	TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:00AM	Entrada Therapeutics Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-10-24 03:29PM	Insiders are Piling into These 5 Healthcare Stocks in 2024 (Insider Monkey) -5.72%
Apr-04-24 02:00PM	The United Mitochondrial Disease Foundation Announces Inaugural Venture Philanthropy Investment; The Mito Fund Invests $500k in Pierrepont Therapeutics, Inc. (PR Newswire)
Mar-27-24 01:27AM	Director Peter Kim Acquires 9,048 Shares of Entrada Therapeutics Inc (TRDA) (GuruFocus.com)
Mar-15-24 05:31AM	Entrada Therapeutics Inc (TRDA) Reports Solid Financial Position and Advancements in Clinical Trials (GuruFocus.com)
Mar-13-24 07:00AM	Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +9.76%
Feb-07-24 07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-29-24 08:14AM	Time to Pull the Trigger, Says Oppenheimer About These 3 Stocks (TipRanks)
Jan-03-24 07:00AM	Entrada Therapeutics Promotes Nathan J. Dowden to President (GlobeNewswire) -9.03%
Dec-28-23 07:01AM	Entrada Therapeutics Inc CFO Kory Wentworth Sells 12,500 Shares (GuruFocus.com)
Nov-23-23 11:47AM	Entrada (TRDA) Down on FDA Maintaining Clinical Hold on DMD Drug (Zacks)
Nov-22-23 07:00AM	Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy (GlobeNewswire) -31.85%
Nov-07-23 08:25AM	Entrada Therapeutics, Inc. (TRDA) Surpasses Q3 Earnings and Revenue Estimates (Zacks) +8.63%
08:06AM	Entrada Therapeutics Inc (TRDA) Reports Q3 2023 Earnings, Net Income of $35.5 Million (GuruFocus.com)
07:00AM	Entrada Therapeutics Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-12-23 07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -9.47%
Sep-21-23 07:00AM	Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Sep-16-23 01:01AM	Insider Sell: Entrada Therapeutics Inc CEO Dipal Doshi Sells 1,000 Shares (GuruFocus.com)
Sep-07-23 07:00AM	Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community (GlobeNewswire) +5.48%
Aug-29-23 07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-10-23 07:00AM	Entrada Therapeutics Appoints Gina Chapman to its Board of Directors (GlobeNewswire)
Aug-08-23 08:40AM	Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +10.47%
07:00AM	Entrada Therapeutics Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-04-23 06:36AM	Entrada Therapeutics (NASDAQ:TRDA) pulls back 16% this week, but still delivers shareholders notable 33% return over 1 year (Simply Wall St.)
Aug-01-23 07:00AM	Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Jul-21-23 06:43AM	New Strong Buy Stocks for July 21st (Zacks)
Jun-06-23 07:00AM	Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire) +6.54%
May-15-23 06:03AM	Some Analysts Just Cut Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Estimates (Simply Wall St.)
May-13-23 08:03AM	Entrada Therapeutics, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now (Simply Wall St.)
May-10-23 07:00AM	Entrada Therapeutics Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-30-23 10:26AM	We Think Entrada Therapeutics (NASDAQ:TRDA) Needs To Drive Business Growth Carefully (Simply Wall St.)
Apr-04-23 07:00AM	Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors (GlobeNewswire) -5.07%
Mar-29-23 07:00AM	Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference (GlobeNewswire)
Mar-08-23 06:02AM	Entrada Therapeutics, Inc. (NASDAQ:TRDA) Is About To Turn The Corner (Simply Wall St.) +5.94%
Mar-06-23 07:00AM	Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-27-23 07:00AM	Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-09-23 07:00AM	Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire)
Jan-09-23 07:00AM	Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable (GlobeNewswire) +6.95%
Dec-22-22 08:07AM	Biotech Stock Roundup: MDGL Surges on NASH Data, TRDA, RCUS Down on Updates & More (Zacks) -5.30%
Dec-20-22 10:03AM	Entrada (TRDA) Down on Regulatory Update for DMD Candidate (Zacks) -19.76%
Dec-19-22 04:30PM	Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy (GlobeNewswire) -6.09%
Dec-14-22 10:24AM	Biotech Stock Roundup: HZNP Surges on AMGN Offer, TRDA Gains on VRTX Deal & More (Zacks)
Dec-09-22 01:41PM	Entrada (TRDA) Surges on Collaboration With Vertex for DMI (Zacks) -9.19%
Dec-08-22 04:12PM	Entrada Skyrockets On $250 Million Deal With Vertex In Muscular Dystrophy (Investor's Business Daily) +18.51%
10:58AM	Entrada Therapeutics Stock Gains On Licensing Pact With Vertex For Form Of Neuromuscular Disorder (Benzinga)
08:24AM	Entrada Therapeutics shares jump on collaboration with Vertex (MarketWatch)
07:00AM	Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1) (Business Wire)
Nov-22-22 07:00AM	Entrada Therapeutics to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference (GlobeNewswire)
Nov-07-22 07:00AM	Entrada Therapeutics Reports Third Quarter 2022 Financial Results (GlobeNewswire) -10.02%
Aug-30-22 07:00AM	Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-11-22 07:00AM	Entrada Therapeutics Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-04-22 07:00AM	Entrada Therapeutics Announces Collaboration with the Myotonic Dystrophy Clinical Research Network to Study the Natural History of Myotonic Dystrophy Type 1 (GlobeNewswire)
Jul-19-22 07:00AM	Entrada Therapeutics Appoints Karla MacDonald as Chief Corporate Affairs Officer (GlobeNewswire) +8.81%
Jul-14-22 10:47AM	We're Hopeful That Entrada Therapeutics (NASDAQ:TRDA) Will Use Its Cash Wisely (Simply Wall St.)
Jul-06-22 07:00AM	Entrada Therapeutics to Present at William Blair Biotech Focus Conference (GlobeNewswire)
Jun-01-22 07:00AM	Entrada Therapeutics to Present at Goldman Sachs Global Healthcare Conference (GlobeNewswire) -15.24%
May-12-22 07:00AM	Entrada Therapeutics Reports First Quarter 2022 Financial Results (GlobeNewswire) +10.25%
May-11-22 09:30AM	Entrada Therapeutics Presents New Data Supporting its Growing Pipeline of Endosomal Escape Vehicle (EEV) Therapeutics at TIDES USA 2022 (GlobeNewswire) -9.44%
May-10-22 07:00AM	Entrada Therapeutics to Present at H.C. Wainwright Global Investment Conference (GlobeNewswire) +13.84%
Mar-15-22 07:00AM	Entrada Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire) +9.78%

Entrada Therapeutics, Inc. operates as a biotechnology company. It focuses on delivery of biomolecules into the cell to treat devastating diseases. The firm offers intracellular enzyme replacement therapy and protein-protein interaction inhibitors programs. The company focuses on creating and expanding a pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to target and engage underlying drivers of diseases. Entrada Therapeutics was founded by Dehua Pei in 2016 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WENTWORTH KORY JAMES	Chief Financial Officer	Apr 03 '25	Option Exercise	2.10	11,134	23,381	120,670	Apr 04 04:34 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Mar 17 '25	Sale	10.67	1,784	19,035	109,536	Mar 19 04:32 PM
KORY WENTWORTH	Officer	Mar 17 '25	Proposed Sale	10.81	1,784	19,285		Mar 17 04:32 PM
MPM BIOVENTURES 2018, L.P.	10% Owner	Dec 10 '24	Sale	20.77	22,935	476,360	4,402,849	Dec 12 05:00 PM
MPM BIOVENTURES 2018, L.P.	10% Owner	Dec 11 '24	Sale	20.23	21,787	440,751	4,381,062	Dec 12 05:00 PM
MPM BioVentures 2014, L.P.	10% Owner	Dec 10 '24	Sale	20.77	22,935	476,360	4,402,849	Dec 12 05:00 PM
MPM BioVentures 2014, L.P.	10% Owner	Dec 11 '24	Sale	20.23	21,787	440,751	4,381,062	Dec 12 05:00 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Dec 02 '24	Option Exercise	2.10	5,000	10,500	78,849	Dec 03 05:26 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Nov 29 '24	Option Exercise	2.10	1,000	2,100	74,849	Dec 03 05:26 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Dec 02 '24	Sale	20.00	5,000	99,978	73,849	Dec 03 05:26 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Nov 29 '24	Sale	19.97	1,000	19,970	73,849	Dec 03 05:26 PM
Sethuraman Natarajan	President, Research & Develop.	Dec 03 '24	Sale	20.15	11,703	235,786	144,997	Dec 03 05:24 PM
Sethuraman Natarajan	President, Research & Develop.	Dec 02 '24	Sale	20.26	4,088	82,834	156,700	Dec 03 05:24 PM
Sethuraman Natarajan	President, Research & Develop.	Nov 29 '24	Sale	20.00	100	2,000	160,788	Dec 03 05:24 PM
Sethuraman Natarajan	President, Research & Develop.	Nov 13 '24	Sale	20.04	2,700	54,109	160,888	Nov 13 04:49 PM
Sethuraman Natarajan	President, Research & Develop.	Nov 11 '24	Sale	20.01	1,409	28,191	163,588	Nov 13 04:49 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Nov 11 '24	Option Exercise	2.10	6,000	12,600	82,486	Nov 13 04:47 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Nov 11 '24	Sale	19.98	8,637	172,562	73,849	Nov 13 04:47 PM
NATARAJAN SETHURAMAN	Officer	Nov 11 '24	Proposed Sale	19.82	18,762	371,863		Nov 12 07:54 AM
KORY WENTWORTH	Officer	Nov 11 '24	Proposed Sale	19.82	14,637	290,105		Nov 12 07:53 AM
Sethuraman Natarajan	President, Research & Develop.	Nov 06 '24	Sale	18.85	12,299	231,776	164,997	Nov 06 04:36 PM
Sethuraman Natarajan	President, Research & Develop.	Nov 05 '24	Sale	18.18	5,171	94,006	177,296	Nov 06 04:36 PM
Sethuraman Natarajan	President, Research & Develop.	Nov 04 '24	Sale	18.02	749	13,498	182,467	Nov 06 04:36 PM
Sethuraman Natarajan	President, Research & Develop.	Oct 16 '24	Sale	18.00	600	10,800	183,216	Oct 18 04:31 PM
NATARAJAN SETHURAMAN	Officer	Oct 16 '24	Proposed Sale	17.53	20,057	351,599		Oct 16 04:25 PM
Dowden Nathan J	President & COO	Sep 26 '24	Sale	16.00	847	13,552	125,149	Sep 30 04:32 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Sep 09 '24	Sale	14.97	3,195	47,832	76,486	Sep 10 04:34 PM
Dowden Nathan J	President & COO	Sep 09 '24	Sale	15.07	1,904	28,690	125,996	Sep 10 04:33 PM
Dowden Nathan J	President & COO	Sep 06 '24	Sale	15.19	399	6,063	127,900	Sep 10 04:33 PM
Sethuraman Natarajan	Chief Scientific Officer	Sep 09 '24	Sale	15.09	2,642	39,862	183,816	Sep 10 04:32 PM
Sethuraman Natarajan	Chief Scientific Officer	Sep 06 '24	Sale	15.24	600	9,141	186,458	Sep 10 04:32 PM
KORY WENTWORTH	Officer	Sep 09 '24	Proposed Sale	14.80	3,195	47,286		Sep 09 04:27 PM
NATHAN DOWDEN	Officer	Sep 06 '24	Proposed Sale	15.39	3,150	48,478		Sep 06 04:19 PM
Dowden Nathan J	President & COO	Aug 16 '24	Option Exercise	1.74	20,000	34,800	157,204	Aug 20 04:33 PM
Dowden Nathan J	President & COO	Aug 16 '24	Sale	16.27	27,097	440,801	130,107	Aug 20 04:33 PM
NATHAN DOWDEN	Officer	Aug 16 '24	Proposed Sale	16.26	27,097	440,597		Aug 16 04:25 PM
Sethuraman Natarajan	Chief Scientific Officer	Jul 15 '24	Sale	18.00	638	11,484	188,814	Jul 16 04:43 PM
Sethuraman Natarajan	Chief Scientific Officer	Jul 12 '24	Sale	18.00	600	10,800	189,452	Jul 16 04:43 PM
Doshi Dipal	CEO	Jul 15 '24	Sale	17.81	1,600	28,497	334,475	Jul 16 04:42 PM
Doshi Dipal	CEO	Jul 12 '24	Sale	18.00	300	5,400	336,075	Jul 16 04:42 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Jul 08 '24	Sale	14.95	1,758	26,282	81,412	Jul 10 04:34 PM
Doshi Dipal	CEO	Jun 13 '24	Sale	16.17	1,000	16,174	336,375	Jun 14 04:32 PM
KIM PETER S	Director	Jun 03 '24	Option Exercise	6.06	11,918	72,223	104,330	Jun 05 04:31 PM
Sethuraman Natarajan	Chief Scientific Officer	May 20 '24	Sale	15.19	9,675	146,944	190,052	May 20 05:26 PM

ITOS

ITeos Therapeutics Inc

HOWL

Werewolf Therapeutics Inc

TRDA

Entrada Therapeutics Inc

Upgrade your FINVIZ experience